FrancophonIA/ELRC3.0 huggingface dataset:
English: Concomitant administration of Victrelis with sirolimus requires significant dose reduction and prolongation of the dosing interval for sirolimus, with close monitoring of sirolimus blood concentrations and frequent assessments of renal function and sirolimus-related side effects.
Danish: Samtidig administration af Victrelis og sirolimus kræver væsentlig dosisreduktion og forlængelse af dosisintervallet for sirolimus med tæt monitorering af sirolimusblodkoncentrationen samt hyppig overvågning af nyrefunktion og for sirolimusrelaterede bivirkninger.
English: • antiarrhythmic medicines- amiodarone, quinidine
Danish: • medicin til behandling af uregelmæssig hjerterytme - amiodaron, quinidin
English: The treatment discontinuation rate due to anaemia was 2% (5/249) in subjects randomized to receive ribavirin dose reduction and 2% (6/251) in subjects randomized to receive erythropoietin.
Danish: Seponeringsraten på grund af anæmi var 2 % (5/249) hos forsøgspersoner randomiseret til reduktion af ribavirindosis og 2 % (6/251) hos de forsøgspersoner, der var randomiseret til erythropoietin.
English: Discontinuation of therapy is recommended in all patients with 1) HCV-RNA levels of greater than or equal to 1,000 IU per mL at TW 8; or 2) HCV-RNA levels of greater than or equal to 100 IU per mL at TW 12; or 3) confirmed, detectable HCV-RNA levels at TW 24.
Danish: Det anbefales at seponere behandlingen hos alle patienter med 1. hcv-RNA-koncentration højere end eller lig med 1.000 IE/ml i behandlingsuge 8, eller 2. hcv-RNA-koncentration højere end eller lig med 100 IE/ml i behandlingsuge 12, eller 3. bekræftet, detekterbart hcv-RNA i behandlingsuge 24.
English: • Peginterferon alfa-2b + ribavirin for 48 weeks (PR48).
Danish: • Peginterferon alfa-2b + ribavirin i 48 uger (PR48).
English: Safety and efficacy of Victrelis, in combination with peginterferon alfa and ribavirin, have not been studied in patients with decompensated cirrhosis.
Danish: Victrelis' sikkerhed og virkning i kombination med peginterferon alfa og ribavirin er ikke undersøgt hos patienter med dekompenseret cirrose.
English: 1 plasma HCV-RNA at Follow-up Week (FW) 24.
Danish: 1 plasma hcv-RNA ved opfølgningsuge (FW) 24.
English: If the patient has hepatitis C virus ribonucleic acid (HCV-RNA) results greater than or equal to 1,000 IU/mL at TW 8; then discontinue three-medicine regimen.
Danish: Hvis patientens hepatitis C-virus RNA (hcv-RNA)-koncentration er større end eller lig med 1.000 IE/ml i behandlingsuge 8, afsluttes tre-stofbehandlingen.
English: It is not recommended to co-administer darunavir/ritonavir and Victrelis.
Danish: Samtidig administration af darunavir/ritonavir og Victrelis frarådes.
English: Plasma concentrations of calcium channel blockers may increase when administered with Victrelis.
Danish: Calciumantagonisternes plasmakoncentration kan stige, når de administreres sammen med Victrelis.
English: Angioedema (see section 4.4), drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, Stevens-Johnson syndrome Musculoskeletal and connective tissue disorders Arthralgia, myalgia
Danish: 4.4), lægemiddelinduceret udslæt med eosinofili og systemiske symptomer (DRESSsyndrom), Stevens-Johnsons syndrom
English: Since Victrelis is prescribed with peginterferon alfa and ribavirin, please also refer to the respective Summary of Product Characteristics of peginterferon alfa and ribavirin.
Danish: Da Victrelis bliver ordineret sammen med peginterferon alfa og ribavirin, henvises også til produktresumeerne for henholdsvis peginterferon alfa og ribavirin.
English: • lumefantrine and halofantrine - anti-malaria medicines
Danish: • lumefantrin og halofantrin - medicin til behandling af malaria
English: No dose adjustment is necessary when coadministered with Victrelis.
Danish: Dosisjustering er ikke nødvendig ved administration sammen med Victrelis.
English: • However, if it is less than 2 hours before your next dose is due, skip the missed dose.
Danish: • Hvis der derimod er mindre end 2 timer til, at du skal tage din næste dosis, skal du springe den
English: Not known (frequency cannot be estimated from the available data) Skin and hair: Severe rash, which may be accompanied by fever, fatigue, swelling of the face or lymph glands, increase of eosinophils (type of white blood cells), effects on liver, kidney or lung (a reaction called DRESS); serious skin reaction, including blistering or peeling of the skin (a reaction called Stevens-Johnson syndrome)
Danish: Ikke kendt (hyppigheden kan ikke bestemmes ud fra forhåndenværende data) Hud og hår: alvorligt udslæt eventuelt med feber, udmattelse, hævelser i ansigtet eller hævede lymfekirtler, stigning i eosinofile granulocytter (en type hvide blodlegemer), påvirkning af lever, nyrer eller lunger (en reaktion kaldet DRESS); alvorlig hudreaktion herunder blæredannelse og afskalning af huden (Stevens-Johnsons syndrom) Nyrer: nedsat nyrefunktion (bliver generelt normal igen, efter behandlingen er afsluttet)
English: Victrelis is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy (see sections 4.4 and 5.1).
Danish: Victrelis er indiceret til behandling af kronisk hepatitis C (CHC) genotype 1-infektion, i kombination med peginterferon alfa og ribavirin, hos voksne patienter med kompenseret leversygdom, som ikke tidligere er behandlet eller hvor tidligere behandling har svigtet (se pkt.
English: 938/non-Black and Cohort 2 /Black N=159) and stratified by HCV genotype (1a or 1b) and by HCVRNA viral load (≤ 400,000 IU/mL vs. > 400,000 IU/mL) to one of the following three treatment arms:
Danish: Forsøgspersonerne blev randomiseret i et 1:1:1 forhold i to kohorter (Kohorte 1 N= 938/ikke-sorte og Kohorte 2/sorte N=159) og stratificeret i henhold til hcv-genotype (1a eller 1b) og hcv-RNA viral-load (≤ 400.000 IE/ml vs. > 400,000 IE/ml) til en af følgende tre behandlingsarme:
English: Subjects with these baseline variants and reduced response to peginterferon alfa-2b/ribavirin represented approximately 1% of the total number of
Danish: Forsøgspersoner med disse baseline-varianter og reduceret peginterferon alfa-2b/ribavirin respons repræsenterede ca. 1 % af det samlede antal forsøgspersoner, der var blevet behandlet med boceprevir.
English: The number of subjects with cirrhosis is limited (where 39 subjects were treated with Victrelis of
Danish: Antallet af forsøgspersoner med cirrose er begrænset (hvor 39 ud af de 49 forsøgspersoner blev
English: 9/L) was higher in boceprevir-treated patients (29%) than in placebo-treated patients (17%), in combination with peginterferon alfa-2b and ribavirin.
Danish: Procentdelen af patienter med neutropeni grad 3-4 var højere hos boceprevirbehandlede patienter (29 %) end hos placebobehandlede patienter (17 %) i kombination med peginterferon alfa-2b og ribavirin.
English: Table 5 presents sustained virologic response per treatment arm in previously untreated patients who were early responders and late responders and that received similar therapy up to treatment week 28.
Danish: Tabel 5 viser vedvarende virologisk respons per behandlingsarm hos ikke tidligere behandlede patienter, der var tidlige og sene respondenter, og som fik samme behandling indtil behandlingsuge
English: When co-administration is required, starting with the lowest possible dose of atorvastatin should be considered with titration up to desired clinical effect while monitoring for safety, without exceeding a daily dose of 20 mg. For patients currently taking atorvastatin, the dose of atorvastatin should not exceed a daily dose of 20 mg during co-administration with Victrelis.
Danish: Når samtidig administration er nødvendig, bør der startes op med den lavest mulige dosis atorvastatin og optitreres til den ønskede kliniske effekt under samtidig monitorering af bivirkninger og uden at overskride en døgndosis på 20 mg.
English: 9/L (Grade 4 neutropenia) compared to 4% of subjects receiving only peginterferon alfa-2b and ribavirin.
Danish: 9/l (grad 4 neutropeni) sammenlignet med 4 % af de forsøgspersoner, der fik peginterferon alfa-2b og ribavirin alene.
English: %, (n/N) 73 (80/110) 79 (90/114) EOT %, (n/N) 86 (95/110) 89 (101/114) Relapse
Danish: %, (n/N) 25 (17/67) 79 (90/114) 25 (17/67) EOT %, (n/N) 37 (25/67) 89 (101/114) 37 (25/67) Tilbagefald
English: Table 3 Adverse reactions in combination with Victrelis with peginterferon alfa-2b and ribavirin reported during clinical trials
Danish: Bivirkninger for kombinationsbehandling med Victrelis, peginterferon alfa-2b og ribavirin rapporteret under kliniske forsøg
English: Victrelis, in combination with peginterferon alfa and ribavirin, is contraindicated when coadministered with medicines that are highly dependent on CYP3A4/5 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events such as orally administered midazolam and triazolam, bepridil, pimozide, lurasidone, lumefantrine, halofantrine, tyrosine kinase inhibitors, simvastatin, lovastatin, quetiapine, alfuzosin, silodosin, and ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine) (see section 4.3).
Danish: Victrelis er, i kombination med peginterferon alfa og ribavirin, kontraindiceret, når det tages med andre lægemidler, der er stærkt afhængige af CYP3A4/5 clearance, og for hvilke forhøjede plasmakoncentrationer forbindes med alvorlige og/eller livstruende bivirkninger såsom oralt administreret midazolam og triazolam, bepridil, pimozid, lurasidon, lumefantrin, halofantrin, tyrosinkinasehæmmere, simvastatin, lovastatin, quetiapin, alfuzosin, silodosin og sekalealkaloider (dihydroergotamin, ergonovin, ergotamin, methylergonovin) (se pkt.
English: A greater than 10-fold reduction in boceprevir susceptibility was conferred by the amino acid substitutions A156S/T/V, V170A, R155W+A156G and V36M+R155K.
Danish: Mere end 10 gange reduceret følsomhed over for boceprevir opstod ved aminosyre-substitutionerne A156S/T/V, V170A, R155W+A156G og V36M+R155K.
English: Hypotension*, hypertension Deep vein thrombosis*, flushing, pallor, peripheral
Danish: Hypotension*, hypertension Dyb venøs trombose*, rødmen, bleghed, perifer kulde
English: The race distribution of subjects was as follows: 85% White, 12% Black, 1% Asian, < 1% multiracial, < 1% Native Hawaiian or Other Pacific Islander.
Danish: Racefordelingen blandt forsøgspersonerne var således: 85 % hvide, 12 % sorte, 1 % asiater, < 1 % multirace, < 1 % indfødte hawaiianere eller andre Stillehavs-øboere.
English: If permanent discontinuation of peginterferon alfa is required, then ribavirin and Victrelis must also be discontinued.
Danish: Hvis permanent seponering af peginterferon alfa er påkrævet, skal ribavirin og Victrelis også seponeres.
English: Peelable blisters containing 12 hard capsules (3x4 capsule blister strip).
Danish: Blisterkort med aftrækkelig blisterfolie indeholdende 12 hårde kapsler (3 blisterstrips med 4 kapsler i hver).
English: In clinical trials with the combination of Victrelis, peginterferon alfa-2b and ribavirin compared to peginterferon alfa-2b and ribavirin alone, the median time from the initiation of therapy to onset of haemoglobin less than 10 g/dL was similar (71 days with a range of 15-337 days, and 71 days with a range of 8-337 days, respectively).
Danish: I kliniske studier, der sammenlignede kombinationen af Victrelis, peginterferon alfa-2b og ribavirin med peginterferon alfa-2b og ribavirin alene, var den gennemsnitlige tid fra påbegyndelse af behandling til hæmoglobinkoncentrationen faldt til under 6,2 mmol/l (10 g/dl) næsten ens (henholdsvis 71 dage med et interval på 15-337 dage og 71 dage med et interval på 8-337 dage).
English: If permanent discontinuation of ribavirin is required, then peginterferon alfa and Victrelis must also be discontinued.
Danish: Hvis permanent seponering af ribavirin er påkrævet, skal peginterferon alfa og Victrelis også seponeres.
English: The addition of boceprevir to peginterferon alfa and ribavirin is associated with an additional decrease in haemoglobin concentrations of approximately 1 g/dL by Treatment Week 8 compared to standard of care (see section 4.8).
Danish: Tilføjelse af boceprevir til peginterferon alfa og ribavirin er forbundet med et øget fald i hæmoglobinkoncentration på ca. 0,6 mmol/l i behandlingsuge 8 sammenlignet med standardbehandling (se pkt.
English: No dose adjustment required for Victrelis or raltegravir.
Danish: Dosisjustering er ikke nødvendig for Victrelis eller raltegravir.
English: • hormonal replacement therapy - oestrogen-based medicines
Danish: • hormoner mod overgangsalderen - lægemidler indeholdende østrogen
English: No dose adjustment of Victrelis or rilpivirine is recommended.
Danish: Dosisjustering af Victrelis eller rilpivirin er ikke nødvendig.
English: Mean age of subjects randomized was 49 years.
Danish: Gennemsnitsalderen for de randomiserede forsøgspersoner var 49 år.
English: • medicine used to decrease blood pressure - calcium channel blockers (e.g., amlodipine,
Danish: • medicin, der sænker blodtrykket - calciumantagonister (f.eks. amlodipin, diltiazem, felodipin,
English: No dose adjustment of buprenorphine/naloxone or Victrelis is recommended.
Danish: Dosisjustering af buprenorphin/naloxon eller Victrelis er ikke nødvendig.
English: • CYP3A4 inducer medicines (such as antibiotic medicine - rifampicin, and anticonvulsant medicines - carbamazepine, phenobarbital, phenytoin)
Danish: • medicin, der inducerer CYP3A4 (såsom antibiotika - rifampicin og krampestillende lægemidler
English: Refer to the Summary of Product Characteristics for peginterferon alfa and ribavirin for additional information about how to reduce and/or discontinue the peginterferon alfa and/or ribavirin dose.
Danish: Se produktresume for peginterferon alfa og ribavirin for yderligere information om dosisreduktion og/eller seponering af peginterferon alfa og/eller ribavirin.
English: Deafness*, ear discomfort, hearing impaired
Danish: Døvhed*, øregener, forringet hørelse
English: Stomach and gut: lower stomach pain; pancreatitis Urinary: painful when urinating; burning feeling or difficulty urinating; get up several times during the night to urinate
Danish: Mave og tarme: nedre mave-smerter; betændelse i bugspytkirtlen Urin: smerter ved vandladning; brændende følelse eller problemer med vandladning; står op flere gange om natten, for at lade vandet
English: HMG CoA REDUCTASE INHIBITORS Atorvastatin* (atorvastatin 40 mg single dose + Victrelis 800 mg three times daily)
Danish: HMG CoA REDUKTASEHÆMMERE Atorvastatin* (atorvastatin 40 mg enkeltdosis + Victrelis 800 mg tre gange dagligt)
English: Reminder: Please also read the “Do not use” section of the Package Leaflets for peginterferon alfa and ribavirin before you start taking Victrelis.
Danish: Husk: Læs også punktet “Tag ikke” i indlægssedlerne for peginterferon alfa og ribavirin, før du begynder at tage Victrelis.
English: All subjects with detectable HCV-RNA in plasma at TW 24 were discontinued from treatment.
Danish: Hos alle forsøgspersoner med detekterbart hcv-RNA i plasma i behandlingsuge 24 blev behandlingen seponeret.
English: 4.3 Contraindications
Danish: 4.8 Bivirkninger
English: In subjects with < 1-log10 decline in viral load at TW 4 (poor interferon-responsiveness), treatment with the combination of Victrelis with peginterferon alfa-2b and ribavirin resulted in SVR rates of 28 38%, respectively, compared to 4% in subjects treated with standard of care.
Danish: Hos forsøgspersoner med <1log10 fald i viral-load i behandlingsuge 4 (ringe interferonfølsomhed), resulterede behandling med kombinationen af Victrelis og peginterferon alfa-2b og ribavirin i SVR-rater på henholdsvis 28 38 % sammenlignet med 4 % hos forsøgspersoner, der havde fået standardbehandling.
English: Overall, the presence of baseline RAVs did not appear to have a notable association with treatment response in subjects receiving the combination of boceprevir with peginterferon alfa-2b and ribavirin.
Danish: Tilstedeværelsen af baseline-RAVer syntes ikke at have en afgørende association til behandlingsrespons hos de forsøgspersoner, der fik boceprevir og peginterferon alfa-2b og ribavirin.
English: Tel: +43 (0) 1 26 044 msd-medizin@merck.com
Danish: Tel: +43 (0) 1 26 044 msd-medizin@merck.com msd_info@merck.com
English: No dose adjustment of digoxin or Victrelis is recommended.
Danish: Dosisjustering af digoxin eller Victrelis er ikke nødvendig.
English: Use of ribavirin dose reduction versus erythropoietin in the management of anaemia in previously
Danish: Reduktion af ribavirindosis versus erythropoietin i behandlingen af anæmi hos tidligere ubehandlede personer
English: HIV Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Danish: Hiv-non-nukleosid revers transkriptase-hæmmere (NNRTI)
English: The onset of anaemia has been reported with peginterferon alfa and ribavirin therapy by Treatment Week 4.
Danish: Debut af anæmi er rapporteret i forbindelse med peginterferon alfa- og ribavirin-behandling i behandlingsuge 4.
English: In clinical trials, HCV-RNA in plasma was measured with the Roche COBAS Taqman 2.0 assay with a limit of detection of 9.3 IU/mL and a limit of quantification of 25 IU/mL.
Danish: I kliniske forsøg blev hcv-RNA i plasma målt med Roche COBAS Taqman 2.0, med en detektionsgrænse på 9,3 IE/ml og en kvantifikationsgrænse på 25 IE/ml.
English: The concomitant use of Victrelis with doxazosin and tamsulosin is not recommended (see section 4.5).
Danish: Samtidig brug af Victrelis og doxazosin og tamsulosin frarådes (se pkt.
English: The median times for the most relevant boceprevir-resistant variants observed in genotype 1a patients (> 10%) to become undetectable were as follows: R155K+V36M, 0.69 years; V36M, 0.89 years; R155K+T54S, 1.05 years; R155K, 1.08 years; and T54S, 1.14 years.
Danish: Mediantiderne, før de mest relevante boceprevir-resistente varianter set hos genotype 1a-patienter (>10 %) blev ikke-detekterbare, var følgende: R155K+V36M: 0,69 år; V36M: 0,89 år; R155K+T54S: 1,05 år; R155K: 1,08 år; og T54S: 1,14 år.
English: • birth control medicines - drospirenone
Danish: • præventionsmidler - drospirenon
English: Anxiety*, depression*, insomnia, irritability Affect lability, agitation, libido disorder, mood altered,
Danish: Angst*, depression*, insomni, irritabilitet Affekt labilitet, uro, libidoforstyrrelser, humørændringer, søvnforstyrrelser
English: Dose modifications due to anaemia/haemolytic anaemia occurred twice as often in patients treated with the combination of Victrelis with peginterferon alfa-2b and ribavirin (26%) compared to peginterferon alfa-2b and ribavirin alone (13%).
Danish: Dosismodifikation på grund af anæmi/hæmolytisk anæmi forekom dobbelt så ofte hos patienter, der blev behandlet med kombinationen af Victrelis med peginterferon alfa-2b og ribavirin (26 %) som hos dem, der blev behandlet med peginterferon alfa-2b og ribavirin alene (13 %).
English: Anaemia was observed in 49% of subjects treated with the combination of Victrelis with peginterferon alfa-2b and ribavirin compared with 29% of subjects treated with peginterferon alfa-2b and ribavirin alone.
Danish: Anæmi blev observeret hos 49 % af forsøgspersonerne behandlet med kombinationen af Victrelis, peginterferon alfa-2b og ribavirin sammenlignet med 29 % af forsøgspersonerne behandlet med peginterferon alfa-2b og ribavirin alene.
English: Acute myocardial infarction*, atrial fibrillation*, coronary artery disease*, pericarditis*, pericardial
Danish: Akut myokardie-infarkt*, atrie-fibrillering*, koronarteriesygdom*, perikarditis*, perikardial effusion
English: • Co-administration with medicines that are highly dependent on CYP3A4/5 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events such as orally administered midazolam and triazolam, bepridil, pimozide, lurasidone, lumefantrine, halofantrine, tyrosine kinase inhibitors, simvastatin, lovastatin, quetiapine, alfuzosin, silodosin, and ergot derivatives (dihydroergotamine, ergonovine, ergotamine,
Danish: • Samtidig administration af lægemidler, der er stærkt CYP3A4/5-afhængige med hensyn til clearance, og hos hvilke stigende plasmakoncentrationer forbindes med alvorlig og/eller livstruende bivirkninger såsom oralt administreret midazolam og triazolam, bepridil, pimozid, lurasidon, lumefantrin, halofantrin, tyrosinkinasehæmmere, simvastatin, lovastatin, quetiapin, alfuzosin, silodosin og sekalealkaloider (dihydroergotamin, ergonovin, ergotamin,
English: Sexual: missing menstrual period; heavy or prolonged menstrual period; uterine bleeding (i.e., prolonged >7 days or excessive bleeding at irregular or more frequent than normal intervals, bleeding occurring in menopausal women at least 6 months to 1 year after cessation of cycles) Mental illness: anger; hostile attitude or behaviour; threatening behaviour; substance abuse problems, abnormal behaviour; feeling of confusion; thoughts of suicide; sudden intense fear or apprehension; feeling you are being persecuted; difficulty solving problems Muscles: pain in your bones; local or widespread pain
Danish: Endetarm eller endetarmsåbning: anal kløe; kan ikke komme af med afføring eller misfarvet afføring; hyppigere tarmbevægelser; blødning fra anus Seksuelt: udeblivende menstruation; voldsom eller forlænget menstruation; blødning i livmoder (dvs. vedvarende >7 dage eller overdreven blødning med uregelmæssige intervaller eller hyppigere intervaller end normalt, blødning, der forekommer hos kvinder i overgangsalderen i mindst 6 måneder til 1 år efter menstruationens ophør) Psykisk sygdom: vrede; fjendtlig attitude eller opførsel; truende adfærd; stofmisbrugsproblemer; unormal opførsel; følelse af forvirring; selvmordstanker; pludselig, voldsom frygt eller ængstelse; følelse af at blive forfulgt; besvær med at løse problemer Muskler: smerter i dine knogler; lokal eller omfattende smerte
English: In clinical trials, HCV-RNA in plasma was measured with a Roche COBAS Taqman assay with a limit of detection of 9.3 IU/mL and a limit of quantification of 25 IU/mL.
Danish: I kliniske forsøg blev hcv-RNA i plasma målt med en Roche COBAS Taqman test med en detektionsgrænse på 9,3 IE/ml og en kvantifikationsgrænse på 25 IE/ml.
English: The activity of boceprevir against the HCV genotype 1b replicon was reduced (2- to 8-fold) by the following amino acid substitutions in the NS3 protease domain: V36A/M, F43S, T54A/G/S, V55A, R155K/G, V158I, V170M and M175L.
Danish: Boceprevirs aktivitet mod hcv-genotype 1b-replikonet blev reduceret (2 - 8 gange) af følgende aminosyre-substitutioner in NS3-proteasedomænet: V36A/M, F43S, T54A/G/S, V55A, R155K/G, V158I, V170M og M175L.
English: The distribution of subjects by gender was 60% men and 40% women.
Danish: Kønsfordelingen af forsøgspersoner var 60 % mænd og 40 % kvinder.
English: The activity of boceprevir against the HCV genotype 1a replicon was reduced (2- to 6-fold) by the following amino acid substitutions in the NS3 protease domain: V36A/L/M, Q41R, T54A/S, V55A, R155K and V158I.
Danish: Boceprevirs aktivitet mod hcv-genotype 1a-replikonet blev reduceret (2 - 6 gange) af følgende aminosyre-substitutioner i NS3-proteasedomænet: V36A/L/M, Q41R, T54A/S, V55A, R155K og V158I.
English: In medicine interaction trials conducted with AKR inhibitors diflunisal and ibuprofen, boceprevir exposure did not increase to a clinically significant extent.
Danish: I lægemiddelinteraktionsforsøg udført med AKR-hæmmerne diflunisal og ibuprofen øgedes boceprevir-eksponeringen ikke i klinisk signifikant grad. Victrelis kan anvendes samtidig med AKR-hæmmere.